Attenuation of bleomycin-induced pulmonary fibrosis by intratracheal administration of antisense oligonucleotides against angiotensinogen mRNA

Current Pharmaceutical Design

Volumn 13, Issue 12, 2007, Pages 1257-1268

  Li, Xiaopeng ^a   Zhuang, Jiaju ^a   Rayford, Heather ^a   Zhang, Huiying ^a   Shu, Ruijie ^a   Uhal, Bruce D ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Alveolar epithelial cells; Angiotensin; Antisense oligonucleotides; Apoptosis; Pulmonary fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; ANGIOTENSINOGEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; BLEOMYCIN; CASPASE 3; HYDROXYPROLINE; MESSENGER RNA;

AMINO ACID ANALYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MECHANISM; HORMONE BLOOD LEVEL; HORMONE INHIBITION; HORMONE SYNTHESIS; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VIVO STUDY; KIDNEY; LIVER; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS WALL; LUNG FIBROSIS; MALE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; UPREGULATION;

ANGIOTENSINOGEN; ANIMALS; BLEOMYCIN; DRUG ADMINISTRATION ROUTES; MALE; OLIGONUCLEOTIDES, ANTISENSE; PULMONARY FIBROSIS; RATS; RATS, WISTAR; RESPIRATORY MUCOSA; RNA, MESSENGER; TRACHEA;

EID: 34248397257     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780618867     Document Type: Review

References (61)

1. Fonseca C, Abraham D, Black CM. Lung fibrosis. Springer Semin Immunopathol 2000; 453-74.
2. Selman M, King TE, Pardo A. Idiopathic PF: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.
3. King TE Jr. Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment International Consensus Statement, Am J Respir Crit Care Med. 2000; 161: 646-64.
4. Mason RJ, Schwarz MI, Hunninghake GW, Musson RA. NHLBI Workshop Summary. Pharmacological therapy for idiopathic PF. Past, present, and future. Am J Respir Crit Care Med 1999; 160: 1771-7.
5. Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, et al. Future research directions in idiopathic PF: Summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2002; 166: 236-46.
6. Gauldie J, Kolb M, Sime PJ. A new direction in the pathogenesis of idiopathic pulmonary fibrosis? Respir Res 2002; 3: 1.
7. Haschek WM, Witschi H. PF - a possible mechanism. Toxicol Appl Pharmacol 1979; 51: 475-87.
8. Witschi H. Responses of the lung to toxic injury, Environ Health Perspect 1990; 85: 5-13.
9. Uhal BD, Joshi I, Hughes WF, Ramos C, Pardo A, Selman M. AEC death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 1998; 275: L1192-9.
10. Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced PF in mice. Am J Respir Cell Mol Biol 1997; 16: 91-101.
11. Hagimoto N, Kuwano K, Miyazaki H, Kunitake R, Fujita M, Kawasaki M, et al. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of FAS antigen. Am J Respir Cell Mol Biol 1997; 17: 272-8.
12. Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD. Abrogation of bleomycin-indaced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2000; 279: L143-51.
13. Kuwano K, Kunitake R, Maeyama T, Hagimoto N, Kawasaki M, Matsuba T, et al. Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2001; 280: L316-25.
14. Kuwano K, Kunitake R, Kawasaki M, Nomoto. Y, Hagimoto N, Nakanishi Y, et al. P21Wafl/Cipl/Sdil and p53 expression in association with DNA strand breaks in idiopathic PF. Am J Respir Crit Care Med 1996; 154: 477-83.
15. Wang R, Zagariya A, Ang E, Ibarra-Sunga O, Uhal BD. Fas-induced apoptosis of AECS requires ANG II generation and receptor interaction. Am J Physiol 1999; 277: L1245-50.
16. Wang R, Alam G, Zagariya A, Gidea C, Pinillos H, Lalude O, et al. Apoptosis of lung epithelial cells in response to TNF-alpha requires ANG II generation de novo. J Cell Physiol 2000; 185: 253-9.
17. Li X, Zhang H, Soledad-Conrad V, Zhuang J, Uhal BD. Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol Lung Cell Mol Physiol 2003; 284: L501-7.
18. Uhal BD. Epithelial apoptosis in the initiation of lung fibrosis. Eur Respir J Suppl 2003; 44: 7s-9s.
19. Filippatos G, Uhal BD. Blockade of apoptosis by ACE inhibitors and angiotensin receptor antagonists. Curr Pharm Des 2003; 9: 707-14.
20. Taylor BK, Stoops TD, Everett AD. Protein phosphatase inhibitors arrest cell cycle and reduce branching morphogenesis in fetal rat lung cultures. Am J Physiol Lung Cell Mol Physiol 2000; 278: L1062-70.
21. Woessner J. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440-7.
22. Mundle S, Iftikhar A, Shetty V, Alvi S, Dameron S, Gregory S, et al. In situ end labeling of DNA to detect apoptotic cell death in a variety of human tumors. Cell Death Differ 1994; 1: 117-22.
23. Panoskaltisis-Mortari, Bucy. In situ hybridization with digoxigenin RNA probes: Fact and artifacts. Biotechniques 1995; 18:300-7.
24. Fehrenbach H, Kasper M, Koslowski R, Pan T, Schuh D, Muller M, et al. Alveolar epithelial type II cell apoptosis in vivo during resolution of keratinocyte growth factor-induced hyperplasia in the rat. Histochem Cell Biol 2000; 114: 49-61.
25. van Kats JP, Danser AH, van Meegen JR, Sassen LM, Verdouw PD, Schalekamp MA. Angiotensin production by the heart: A quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998; 98: 73-81.
26. Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, Schalekamp MA. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994; 35: 1008-18.
27. Lindpaintner K, Jin M, Wilhelm MJ, Suzuki F, Linz W, Schoelkens BA, et al. Intracardiac generation of angiotensin and its physiologic role. Circulation 1988; 77: 118-23.
28. Li D, Yang B, Philips MI, Mehta JL. Proapoptotic effects of ANG II in human coronary artery endothelial cells: Role of AT1 receptor and PKC activation. Am J Physiol 1999; 276: H786-92.
29. Campbell DJ, Habener JF. ANGEN gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest 1986; 78: 31-9.
30. Dzau VJ, Brenner A, Emmett NL. Evidence for renin in Tat brain: differentiation from other reninlike enzymes. Am J Physiol 1982; 242: E292-7.
31. Ohkubo H, Nakayama K, Tanaka T, Nakanishi S. Tissue distribution of rat ANGEN mRNA and structural analysis of its heterogeneity. J Biol Chem 1986; 261: 319-23.
32. Filippatos GS, Gangopadhyay N, Lalude O, Parameswaran N, Said SI, Spielman W, et al. Regulation of apoptosis by vasoactive peptides. Am J Physiol Lung Cell Mol Physiol 2001; 281: L749-61.
33. Morrison CD, Papp AC, Hejmanowski AQ, Addis VM, Prior TW. Increased D allele frequency of the angiotensin-converting enzyme gene in PF. Hum Pathol 2001; 32: 521-8.
34. Kasper M, Lackie P, Haase M, Schuh D, Muller M. Immunolocalization of cathepsin D in pneumocytes of normal human lung and in PF. Virchows Arch 1996; 428: 207-15.
35. Koslowski R, Knoch K, Kuhlisch E, Seidel D, Kasper M. Cathepsins in bleomycin induced lung injury in mt. Eur Respir J 2003; 22: 427-35.
36. Venkatesan N, Punithavathi V, Chandrakasan G. Curcumin protects bleomycin-induced lung injury in rats. Life Sci 1997; 61: 51-8.
37. Specks U, Martin WJ 2nd, Rohrbach MS. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. Am Rev Respir Dis 1990; 141: 117-23.
38. Ward WF, Molteni A, Ts'ao CH, Hinz JM. Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int J Radiat Oncol Biol Phys 1990; 19: 1405-9.
39. Uhat BD. Apoptosis in lung fibrosis and repair. Chest 2002; 122: S293-8.
40. Molteni A, Ward WF, Ts'ao CH, Solliday N-H, Dunne M. Monocrotaline-induced PF in rats: Amelioration by captopril and penicillamine. Proc Soc Exp Biol Med 1985; 180: 112-20.
41. Molteni A, Moulder JE, Cohen EF, Ward WF, Fish BL, Taylor JM, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an ANG II type I receptor blocker. Int J Radiat Biol 2000; 76: 523-32.
42. Fang X, Zhu Y, Hu X, Liu Y. Losartan in the rat model of bleomycin-induced pulmonary fibrosis and its impact on the expression of monocyte chemoattractant protein-1 and basic fibroblast growth factor. Zhonghua he He He Hu Xi Za Zhi 2002; 25: 268-72.
43. Li X, Rayford H, Uhal BD. Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am J Pathol 2003; 163: 2523-30.
44. Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, et al. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type I receptor. Am J Respir Crit Care Med 2000; 161: 1999-2004.
45. Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type I receptor antagonist. Thorax 2004; 59: 31-8.
46. Bargout R, Jankov A, Dincer E, Wang R, Komodromos T, Ibarra-Sunga O, et al. Amiodarone induces apoptosis of human and rat AECS in vitro, Am J Physiol Lung Cell Mol Physiol 2000; 278: L1039-44.
47. Wang R, Ramos C, Joshi I, Zagariya A, Pardo A, Selman M, et al. Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. Am J Physiol 1999; 277: L1158-64.
48. Gyurko R, Wielbo D, Phillips MI. Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pept 1993; 49: 167-74.
49. Wielbo D, Simon A, Phillips MI, Toffolo S. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension 1996; 28: 147-51.
50. Wielbo D, Sernia C, Gyurko R, Phillips MI. Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 1995; 25: 314-9.
51. Peng JF, Kimura B, Fregly MJ, Phillips MI. Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood. Hypertension 1998; 31: 1317-23.
52. Kagiyama S, Varela A, Phillips MI, Galb SM. Antisense inhibition of brain renin-angiotensin system decreased blood pressure in chronic 2-kidney, 1 clip hypertensive rats. Hypertension 2001; 37: 371-5.
53. Phillips MI. Gene therapy for hypertension: Sense and antisense strategies. Expert Opin Biol Ther 2001; 1: 655-62.
54. Li B, Hughes JA, Philips MI. Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. Neurochem Intl 1997; 393-403.
55. Campbell JM, Bacon TA, Wickstrom E. Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Methods 1990; 20: 259-67.
56. Templin MV, Levin AA, Graham MJ, Aberg PM, Axelsson BI, Butler M, et al. Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev 2000; 10: 359-68.
57. Ali S, Leonard SA, Kukoly CA, Metzger WJ, Wooles WR, McGinty JF, et al. Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Am J Respir Crit Care Med 2001; 163: 989-93.
58. Uhal BD, Kim JK, Li X, Molina-Molina M. Angiotensin-TGF-beta1 Crosstalk in human idiopathic pulmonary fibrosis: Autocrine mechanisms in myofibroblasts and macrophages. Curr Pharm Des 2007; 13(12): 1247-56.
59. Coppelli FM, Grandis JR. Oligonucleotides as anticancer agents: From the benchside to the clinic and beyond. Curr Pharm Des 2005; 11(22): 2825-40.
60. ET-Andaloussi S, Holm T, Langel U. Cell-penetrating peptides: Mechanisms and applications. Curr Pharm. Des 2005; 11(28): 3597-611.
61. Zatsepin TS, Turner JJ, Oretskaya TS, Gait MJ. Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents. Curr Pharm Des 2005; 11(28): 3639-54.